Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03355235 · ClinicalTrials.gov registry record
Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
A clinical trial of Stem Cell Transplant Complications, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT03355235: Completed study of Stem Cell Transplant Complications, sponsored by Wake Forest University Health Sciences.
NCT03355235 is a study of Stem Cell Transplant Complications that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants, below the 182-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03355235, a study of Stem Cell Transplant Complications, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assessment, Self-Administered Gerocognitive Exam (SAGE) or the healthcare applied Montreal Cognitive Assessment (MoCA) assessment.
Primary Outcome
Will be assessed by Patient Reported Outcomes Measurement Information System (PROMIS) Cognitive Function, short form 8a. The mean scores (and standard deviations) for each time points will be presented.
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2019-08-27 |
What the finished NCT03355235 record still lists
NCT03355235 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 182-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 0 interventions.
NCT03355235 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03355235 about?
NCT03355235 is a clinical study titled "Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant". The overall objectives in this study are to identify patterns of cognitive impairment pre- and post-transplant, to assess the similarities of scores of the three cognitive assessments in myeloma patients who undergo autologous stem cell transplant, and to determine if patients prefer the self-assess...
What is the current status of trial NCT03355235?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2017-10-20. Estimated completion is 2019-08-27.
What conditions does trial NCT03355235 study?
This clinical trial studies the following conditions: Stem Cell Transplant Complications.
Who is sponsoring clinical trial NCT03355235?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03355235 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03355235's enrollment target sits among peer trials
50 9th of 15 higher than 6 of 15 other Stem Cell Transplant Complications trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stem Cell Transplant Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
RECRUITING · Phase 2
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RECRUITING · Phase 3
-
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
RECRUITING
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI